Advanced and Metastatic Esophageal Squamous Cell Carcinoma (ESCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Advanced and metastatic Squamous cell esophageal carcinoma is typically diagnosed at later stages of the disease, often necessitating extensive surgical resection, occasionally in combination with perioperative chemotherapy or neoadjuvant radiochemotherapy. The manifestation of advanced and metastatic Squamous cell esophageal carcinoma is marked by tumor growth, leading to symptoms that include the gradual loss of the ability to swallow solid foods, followed by difficulty ingesting ground food and, ultimately, liquids. In advanced stages, the disease is characterized by polypoid intraluminal masses and a reduction in esophageal distensibility, which may or may not be accompanied by luminal narrowing. The most common complaint in most patients (90%) is progressive dysphagia, typically observed when more than 50% of the lumen is obstructed or when the luminal diameter falls below 13 mm. Squamous cell carcinoma accounts for approximately 90% of all esophageal cancers worldwide and develops from squamous epithelium, progressing from hyperplasia to dysplasia and eventually to cancer. At the molecular level, its pathogenesis is linked to the deregulation of specific genes, notably TP53, NOTCH, and MTOR. Early-stage esophageal cancers often remain asymptomatic or may present with mild, nonspecific symptoms like heartburn, atypical chest pain, or dyspepsia. Alternatively, patients may experience symptoms such as occult blood in their stool or develop iron deficiency anemia. Some individuals may report mild or sporadic dysphagia, odynophagia, or a sensation of having a foreign body in their throat. Typically, these symptoms prompt diagnostic evaluation, which includes an esophagogastroduodenoscopy (EGD) or upper endoscopy, along with a diagnostic mucosal biopsy. Early-stage cancers are discovered during routine upper endoscopic surveillance for Barrett's esophagus in certain cases. The symptoms of esophageal cancer tend to progress rapidly.

·       Esophageal cancer has an overall annual incidence rate ranging from 4.7 to 5.8 cases per 100,000 individuals. The 5-year survival rate for all individuals diagnosed with Squamous cell esophageal cancer falls from 15% to 20%. Additionally, males exhibit a higher incidence of esophageal cancer compared to females.

 

Thelansis’s “Advanced and Metastatic Esophageal Squamous Cell Carcinoma (ESCC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced and Metastatic Esophageal Squamous Cell Carcinoma (ESCC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Advanced and Metastatic Esophageal Squamous Cell Carcinoma (ESCC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Advanced and Metastatic Esophageal Squamous Cell Carcinoma (ESCC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Advanced and Metastatic Esophageal Squamous Cell Carcinoma (ESCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Advanced and Metastatic Esophageal Squamous Cell Carcinoma (ESCC), Advanced and Metastatic Esophageal Squamous Cell Carcinoma (ESCC) market outlook, Advanced and Metastatic Esophageal Squamous Cell Carcinoma (ESCC) competitive landscape, Advanced and Metastatic Esophageal Squamous Cell Carcinoma (ESCC) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more